Tenon Medical, Inc.

Tenon Medical reported a significant increase in revenue, up 106% to $2.66 million for the six months ended June 30, 2026, but its net loss widened to $(7.53) million. The company issued a going concern warning, indicating insufficient funds for the next 12 months. To address Nasdaq compliance, Tenon Medical completed a 1-for-35 reverse stock split in August 2026 and regained compliance with the minimum stockholders' equity rule after a July 2026 public offering.

Tenon Medical, Inc. reported strong financial growth for the second quarter ended June 30, 2026, with revenue increasing 127% to $1.3 million and gross profit surging 232% to $0.8 million. The company also achieved a 64% gross margin, a significant improvement from the prior year. However, net loss widened to $4.1 million, and cash reserves decreased to $1.7 million by quarter-end. Subsequent to the quarter, Tenon Medical secured FDA clearance for its updated Catamaran® SI Joint Fusion System, closed a $4.2 million public offering, and implemented a 1-for-35 reverse stock split to address Nasdaq listing requirements.

Tenon Medical, Inc. announced and effected a 1-for-35 reverse stock split of its common stock, which became effective on August 10, 2026. The company's shares began trading on a split-adjusted basis on the Nasdaq Capital Market on the same day under the existing symbol "TNON." This action was approved by stockholders on July 23, 2026, and the Board of Directors determined the 1-for-35 ratio, primarily to increase the per share market price to meet Nasdaq's minimum $1.00 average closing price requirement for continued listing.

Tenon Medical, Inc. announced it received notice from Nasdaq on July 17, 2026, confirming it has regained compliance with the Nasdaq Stockholders' Equity Rule. This compliance was achieved following the completion of a $4.2 million public offering of common stock and warrants on July 1, 2026. The company had previously disclosed its belief of compliance in a July 10, 2026 8-K filing. However, Tenon Medical must evidence continued compliance upon filing its Quarterly Report on Form 10-Q for the period ending September 30, 2026, to avoid potential delisting.

Tenon Medical, Inc. announced that it believes it has regained compliance with Nasdaq's minimum stockholders' equity requirement. The company previously received a non-compliance notice on May 21, 2026. Following a public offering on July 1, 2026, which raised $4.2 million from the sale of common stock and warrants, Tenon Medical now believes it satisfies the requirement as of July 10, 2026. Nasdaq will continue to monitor the company's compliance, with potential delisting if non-compliance is not evidenced by the September 30, 2026 Quarterly Report on Form 10-Q.

Tenon Medical, Inc. announced the pricing and closing of a public offering, generating aggregate gross proceeds of $4.2 million. The offering consisted of common stock (or pre-funded warrants) and common stock purchase warrants at a combined price of $0.38 per share. The company plans to use the net proceeds for partial repayment of outstanding convertible notes, expansion of its commercial footprint, research and development, and general corporate purposes.

Tenon Medical, Inc. has filed an S-1 registration statement to register various securities for a potential future offering. The filing details the calculation of fees for common stock, pre-funded warrants, common stock purchase warrants, and underwriter warrants. The total maximum aggregate offering price for these securities is $443,800, with a total registration fee of $61.29.

Tenon Medical, Inc. filed an S-1/A registration statement for a public offering of 1,812,987 shares of common stock, along with common stock purchase warrants for up to 6,975,584 shares and pre-funded warrants for up to 4,000,000 shares. The assumed combined public offering price is $0.6021 per share and accompanying Common Warrants. The company intends to use the net proceeds for partial repayment of outstanding convertible notes, expansion of its commercial footprint, clinical research, R&D, and general corporate purposes. WallachBeth Capital LLC is acting as the exclusive placement agent for this reasonable best efforts offering.

Tenon Medical, Inc. announced its 2026 Annual Meeting of Stockholders, to be held virtually on July 23, 2026. Key proposals include an amendment to its Certificate of Incorporation to effect a reverse stock split at a ratio between 1:2 and 1:35. Shareholders will also vote on approving the issuance of shares related to a March 2026 debt financing and future financings to comply with Nasdaq listing rules, alongside the election of seven directors and the ratification of the company's auditor.

Tenon Medical, Inc. has filed an S-1 registration statement for a public offering of up to 1,812,987 shares of common stock, along with common stock purchase warrants to acquire up to 6,975,584 shares. Additionally, the company is offering pre-funded warrants to purchase up to 4,000,000 shares. The assumed combined public offering price is $0.6021 per share and accompanying Common Warrants, with proceeds intended for commercial expansion, research and development, inventory, and general corporate purposes. The offering will result in immediate dilution for existing shareholders.